TD Cowen initiated coverage of Upstream Bio (UPB) with a Buy rating. The firm says the company’s verekitug is a “differentiated fast follower” with greater potency and extended dosing intervals versus Tezspire. Tge Phase 1 data have shown “rapid, deep, and sustained effects” on asthma biomarkers, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UPB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue